A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)

Trial Profile

A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Diclofenac potassium (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors DepoMed
  • Most Recent Events

    • 10 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 according to ClinicalTrials.gov record.
    • 10 Dec 2015 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top